TrialCancer2025

Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.

Emmanuel Gyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.